People are looking for solutions to their real-life problems. With cannabinoids we are able to address a multi-billion EU-market for sleep, pain and anxiety solutions with cumulative sales of over € 250 billion for OTC and pharmaceuticals in 2020.
over
people with sleep-related problems,
such as disturbed sleep
over
people with chronic pain and
similar issues
over
people with anxiety
SynBiotic’s organizational structure is built to cover all value drivers – from research over production to distribution
Our R&D portfolio consists of leading research facilities, whose scientists are sought-after pioneers in the field of cannabinoids.
With a portfolio of production and extraction companies operating cutting-edge facilities, we can guarantee products of the highest quality – a significant competitive advantage.
Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.
Most CBX* have not been discovered yet, but studies show that other cannabinoids, beyond THC and CBD, have huge medical potential. In addition, the so called entourage effect is a term used to describe the synergistic effects of combining various chemical compounds found in cannabis. Most commonly, it refers to the interaction between THC/CBD and other cannabinoids or terpenes.
* CBX = all cannabinoids except THC
While CBD from hemp & cannabis plants is still a legal grey area, we focus in parallel on other plants that are rich in cannabinoids, endocannabinoids & terpenes.
In addition, we are exploring newer solution, such as programming and growing yeast cultures in bioreactors, which enables the extraction of very rare and specific cannabinoids, such as CBG, in large quantities.
Lorem ipsum dolor sit ame consectetur adipiscing elit,
sed do eiusmod tempor incididunt ut labore.
* all kinds of cannabinoids
Long headline lorem ipsum dolor sit atmet, tempor ut labore magna nisi velit. lorem ipsum dolor sit atmet, tempor ut labore magna nisi velit.
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Börse: Düsseldorf (Freiverkehr)
WKN/ISIN:
A2LQ77 / DE000A2LQ777
Stammkapital: 2.250.000,00 EUR
Aktienanzahl: 2.250.000
Finanzkalender 2020
Oktober 2020
Veröffentlichung des Halbjahresberichtes
Jahresabschlüsse:
Geschäftsjahr 2019 (PDF)
Geschäftsjahr 2018 (PDF)
2020-06-30 • Sachkapitalerhöhung zur Durchführung der Übernahme der Geschäftsanteile an der SOLIDMIND Nutrition GmbH beschlossen
2020-05-19 • Absichtserklärung über eine Übernahme der SOLIDMIND Nutrition GmbH gegen Gewährung von Aktien und Barzahlung
2020-04-27 • Kapitalerhöhung bei EUR 15 je Aktie mit Zeichnungszusage von Michael Auerbach’s Subversive Capital beschlossen
2020-04-16 • Kapitalerhöhung in Höhe von 1,25 Mio. Euro voll platziert
2020-04-08 • Aus der Ledgertech SE wird die SynBiotic SE
SynBiotic supports & invests in cannabinoid focused ventures and teams. Are you looking for a strong partner? Contact us!
Find out more about our company, its structure, shares and download the latest financial publications.
Synbiotic’s recent press publications
The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) has been listed on the Frankfurt Stock Exchange and Xetra since Wednesday, January 6, 2021. The private bank Hauck & Aufhäuser was committed as a designated sponsor.
Das Cannabis-Unternehmen SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77) ist seit Mittwoch, den 6. Januar 2021, an der Frankfurter Börse und auf dem Handelsplatz Xetra gelistet. Als Designated Sponsor wurde die Privatbank Hauck & Aufhäuser verpflichtet.
München, 02. Dezember 2020. Das Cannabis-Unternehmen SynBiotic SE führt derzeit eine Barkapitalerhöhung durch. Bis zum 17. Dezember 2020 sollen bis zu 375.000 neue Aktien am Markt platziert werden. Mit dem
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
Making Cannabinoids accessible.